{'fraction_non_alphanumeric': 0.02418207681365576, 'fraction_numerical': 0.021337126600284494, 'mean_word_length': 5.518518518518518, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Spotlight on the February 11 Issue

The authors measured KIR4.1-IgG in children with acquired demyelinating disease, other neurologic diseases, autoimmune diseases, and controls. Serum antibodies to KIR4.1 were found in the majority of children with acquired demyelinating disease but not in children with other diseases or in controls. These findings suggest that KIR4.1 is an important target of autoantibodies in childhood acquired demyelinating disease.

See p. 470

This study investigated 215 patients with neuromyelitis optica spectrum disorders for clinical findings that distinguish those with myelin oligodendrocyte glycoprotein (MOG) antibodies, those with aquaporin-4 antibodies, and those …